Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27843023 | 0.80 | HIF1A (0.49) | SMN1; SMN2HIF1ASRC | |
| SCHEMBL10133040 | 0.78 | GAA (0.77) | GAAMAPTMEN1KMT2ATDP1 | |
| SCHEMBL10133018 | 0.78 | TUBB4A (0.55) | SRC | |
| SCHEMBL6742452 | 0.77 | CYP1A2 (0.60) | GAAMAPTMEN1KMT2ATDP1 | |
| SCHEMBL10132852 | 0.77 | TUBB4A (0.69) | SRC | |
| SCHEMBL10060315 | 0.76 | GAA (0.80) | GAAMAPTMEN1KMT2ATDP1 | |
| SCHEMBL2846343 | 0.75 | HIF1A (0.56) | MAPTKMT2AHIF1ASRCOPRM1 | |
| SCHEMBL16812954 | 0.73 | SMN1; SMN2 (0.75) | GAAMAPTMEN1KMT2ATDP1 | |
| SCHEMBL18876359 | 0.73 | NPC1 (0.44) | MAPTSMN1; SMN2HIF1ASRC | |
| SCHEMBL6042308 | 0.73 | HRH1 (0.52) | TDP1SMN1; SMN2HIF1ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | GAA 3884/4885MAPT 2664/4885MEN1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.